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Abstract
Background: This phase II study was designed to evaluate the activity and safety of a combination
of epirubicin, oxaliplatin and docetaxel in metastatic gastric or gastroesophageal junction (GEJ)
adenocarcinoma.
Methods:  Forty patients with measurable distant metastases received epirubicin 50 mg/m2,
docetaxel 60 mg/m2 followed by oxaliplatin 100 mg/m2 on day 1 of each 21-day cycle. Primary end
point was response rates (RR).
Results: All patients were evaluable. The overall RR was 47.5% (95% confidence interval (CI) 32–
63). The disease control was 80%. Median time for response was 6 weeks. Median time to
progression was 6.3 months (95% CI 5.4–7.2) and the median overall survival time was 12.1 months
(95% CI 10.7–13.5). Grade 3/4 neutropenia occurred in 50% of patients with two episodes of
febrile neutropenia (5%). Other non-hematological grade 3 toxicities included sensory neuropathy
in two patiens (5%), vomiting and mucositis in two patients (5%) and diarrhea in one patient (2.5%).
Conclusion: The combination of epirubicin, oxaliplatin and docetaxel was found to be effective
and well tolerated in patiens with metastatic gastric or GEJ adenocarcinoma and maybe an
appropriate regimen to be used in the neoadjuvant setting and with molecularly targeted agents.
Background
Gastric cancer is still the second leading cause of cancer
mortality in the world [1], and it has been estimated that
this disease caused in excess of 188,000 deaths in Europe
alone in 2006 [2]. Frequently, patients with gastric cancer
present with metastatic disease and treatment is essen-
tially palliative. Systemic chemotherapy is able to confer a
survival advantage and an improvement in quality of life
when compared with supportive care alone [3]. However,
median time to progression (TTP) is only 4–5 months,
with an overall survival (OS) of 7–9 months [3]. No
standard chemotherapy-regimen exists for advanced gas-
tric cancer, but the combinations of cisplatin with fluor-
ouracil (FU) and anthracyclines remain among the most
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extensively employed regimens, although they are associ-
ated with considerable toxicities [4].
Oxaliplatin, a third generation platinum compound, in
phase II studies has shown activity in combination with
fluoropyrimidines in patients with advanced gastric can-
cer, with response rates (RR) and median OS ranging from
38% to 65% and 8.6 to 11.4 months, respectively [5-9]. In
comparison with cisplatin, oxaliplatin shows a better tox-
icity profile, which translates to patient convenience.
Among taxanes derivatives, docetaxel has emerged as one
of the most active agents in gastric cancer, either as single
agent or in combination with several other drugs [10].
Recently, we reported a 50% RR and a median OS of 11.2
months in 46 metastatic gastric cancer patients treated
with a combination of epirubicin, cisplatin and docetaxel
(ECD) [11].
In an attempt to improve on these results, we performed
a phase II study substituting, in ECD regimen, cisplatin
with oxaliplatin in chemotherapy-naïve patients with
metastatic gastric or gastroesophageal junction (GEJ) ade-
nocarcinoma.
Patients and methods
Patient Selection
Patients with gastric or GEJ adenocarcinoma with distant
metastases not previously treated by systemic chemother-
apy were enrolled onto the study. Adjuvant chemotherapy
without docetaxel or oxaliplatin was allowed if completed
at least 6 months before. Patients were required to have
measurable disease, ECOG performance status ≤ 2, life
expectancy > 3 months, age between 18 and 75 years, ade-
quate bone marrow (absolute neutrophil count ≥ 1,500/
μl, platelet count ≥ 100,000/μl), renal (serum creatinine ≤
1.5 mg/dl) and liver (serum bilirubin ≤ 1.5 mg/dl) func-
tions, normal cardiac function, absence of second primary
tumour other than non-melanoma skin cancer or in situ
cervical carcinoma, no CNS involvement, no prior radio-
therapy in parameter lesions, no concurrent uncontrolled
medical illness. The protocol was approved and carried
out according to the principles of the Declaration of Hel-
sinki and Good Clinical Practice guidelines, and all
patients gave their written informed consent to participate
onto the trial.
Treatment
Treatment consisted of epirubicin 50 mg/m2 by intrave-
nous bolus followed, 15 minutes later by docetaxel 60
mg/m2 diluted in 500 ml of normal saline as 1 h infusion,
and oxaliplatin 100 mg/m2 diluted in 500 ml 5% dextrose
as a 2 h infusion. All drugs were administered on day 1 of
each 21-day cycle. Antiemetic treatment consisted of pal-
onosetron 250 μg plus dexamethasone in a 10 minutes
infusion before starting chemotherapy. In addition, orally
prednisone premedication was used for prophylaxis of
docetaxel-induced hypersensitivity and fluid retention.
Granulocyte colony-stimulating factor (G-CSF) was used
only as secondary prophylaxis once patients had febrile
neutropenia or documented neutropenic infection. Treat-
ment was postponed by a maximum of 2 weeks if the
absolute neutrophil count was less than 1,500/μl or the
platelet count was less than 100,000/μl. The dose of epi-
rubicin was reduced by 25% of the previous dose in case
of grade ≥ 3 stomatitis or diarrhea, whereas oxaliplatin
was reduced by 25% in case of grade ≥ 2 peripheral neu-
ropathy or grade ≥ 3 diarrhea, and docetaxel by 25% in
case of the following toxicities: grade ≥ 3 neutropenia last-
ing more than 7 days (or in presence of fever), second
incidence of febrile neutropenia despite G-CSF support
administered after the first occurrence, grade ≥ 3 diarrhea,
and grade ≥ 3 stomatitis.
Chemotherapy was generally administered on an outpa-
tient basis for a maximum of eight cycles for patients with
objective responses and of six cycles for patients with sta-
ble disease (SD). Treatment was discontinued in case of
unacceptable toxicity, treatment delay longer than 2
weeks, disease progression, or patients refusal.
Pretreatment and Follow-Up Studies
Pretreatment evaluation included clinical history and
physical examination, automated blood cell count, bio-
chemical profile, ECG, and computed tomography of tho-
rax and abdomen. Endoscopy was performed only in case
of complete remission of all measurable lesions. Blood
counts were obtained weekly; biochemical profile was
repeated every 3 weeks. All measurable parameters of dis-
ease were reevaluated every 6 weeks, and every 2 months
during the follow-up period.
Evaluation of Response and Toxicity
Patients were evaluated for response to chemotherapy
every two cycles of treatment. Responses were assessed by
at least two observers, and were confirmed by an expert
independent radiologist. The RECIST criteria were used to
evaluate clinical response [12], and all objective responses
were confirmed by CT scans at least 4 weeks after the ini-
tial documentation of response. TTP and OS were calcu-
lated from the date of first chemotherapy cycle to the date
of disease progression, death or last follow-up evaluation,
respectively. Toxicity was assessed in each treatment cycle
using the National Cancer Institute Common Toxicity Cri-
teria (version 3.0). Peripheral sensitive neuropathy was
graded according to an oxaliplatin-specific scale as
described previously [13].
Statistical Methods
The primary end point of this study was to estimate the
overall response rate of the regimen. Secondary endJournal of Experimental & Clinical Cancer Research 2009, 28:34 http://www.jeccr.com/content/28/1/34
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points were TTP, OS and safety. The Simon's two-stage
phase II design was used to determine the sample size
[14]. An interim analysis was carried out when the first 18
assessable patients had been recruited. If more than 4
responses were observed, 15 additional patients were to
be recruited; otherwise, the study was to be terminated. If
more than 10 responses were observed in the 33 patients,
the regimen was considered sufficiently active with a sig-
nificance level of 5% and power of 80% to be submitted
for further evaluation. Seven additional patients were
recruited in order to improve the statistical power. TTP
and OS were analyzed according to the Kaplan-Meier
method, and were updated to 31 December 2008.
Results
Patients Characteristics
From June 2006 to February 2008, 40 patients with meta-
static gastric or GEJ cancer were enrolled by three onco-
logic Italian centres. All patients were evaluable for
efficacy and toxicity. The pre-treatment characteristics of
patients are listed in Table 1. None of the patients had pre-
viously received chemotherapy for advanced disease; six
patients had received adjuvant chemotherapy without
docetaxel or oxaliplatin several months before they
entered this study (median, 12 months; range, 8–20
months).
Efficacy
Among 40 assessable patients, we observed two (5%)
complete responses (CRs) and 17 (42.5%) partial
responses (PRs), for an overall response rate of 47.5%
(95% CI, 32–63). The disease control (CRs plus PRs plus
SD) was 80% (Table 2). Responses according to predom-
inant site of disease, were as follows: liver, 12 of 24
patients (50%); nodes/peritoneum 5 of 12 patients
(41.7%); lung 1 of 2 patients and bone 1 of 2 patients.
Response rates did not significantly differ according to
number of metastatic sites: one site, 6 of 11 patients
(54.5%); two sites, 9 of 19 patients (47.4%); and three or
more sites, 4 of 10 patients (40%). Responses were seen in
2 of 6 patients (33.3%) who received adjuvant chemo-
therapy and in 17 of 34 patients (50%) not previously
treated with chemotherapy. Responses were observed also
in 13 of 28 patients (46.4%) with primary tumor not
resected and in 6 of 12 patients (50%) with primary
tumor resected. RR did non differ when patients were
evaluated according to the primary site of disease (gastric:
46.7% and GEJ: 50%, respectively). The median time for
response was 6 weeks (range, 6–18). Upon disease pro-
gression, 22 patients (55%) received a second-line chem-
otherapy, including irinotecan/fluorouracil-leucovorin (n
= 18) and cisplatin/capecitabine (n = 4). Median TTP was
6.3 months (95% CI 5.4–7.2) (Figure 1). Only 8 patients
(20%) progressed within the first two months, whereas at
the time of this analysis all but one patient had experi-
enced progressive disease. Median OS was 12.1 months
(95% CI 10.7–13.5 months) (Figure 2). One- and 2-year
survivals were 50.3% and 12.6%, respectively. Thirty-six
patients had died at the time of the present evaluation.
Toxicity
Hematological toxicity data are listed in Table 3. A total of
220 cycles of this epirubicin, oxaliplatin and docetaxel
(EOD) combination were analyzed in 40 patients, with a
median of 6 cycles administered per patient (range, 2–8
cycles). The most important toxicity was myelosuppres-
sion, which occurred almost always on day 8 (docetaxel
Table 1: Patient characteristics
Characteristic No. of patients %
Patients evaluable 40 100
Age, years
Median 65
Range 34–75
Sex
Male 24 60
Female 16 40
ECOG PS
06 1 5
12 7 6 7 . 5
27 1 7 . 5
Disease location
Gastric 30 75
GEJ 10 25
Histologic type
Diffuse 19 47.5
Intestinal 15 37.5
Unspecified 6 15
Previous adjuvant chemotherapy 6 15
Status of primary tumor
Unresected 28 70
Resected 12 30
Predominant site of disease
Liver 24 60
Peritoneum 8 20
Nodes 4 10
Lung 2 5
Bone 2 5
No. of metastatic sites
11 1 2 7 . 5
21 9 4 7 . 5
≥ 31 0 2 5
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group 
Performance Status;
GEJ, gastroesophageal junctionJournal of Experimental & Clinical Cancer Research 2009, 28:34 http://www.jeccr.com/content/28/1/34
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nadir). Grade 3 and 4 neutropenia were recorded in 35%
and in 15% of the patients, respectively. Febrile neutrope-
nia occurred in 2 (5%) patients. In these patients a 25%
dose-reduction of docetaxel was required, whereas treat-
ment was postponed in 2 (5%) patients and in 7 (3.2%)
cycles because of a delay in bone marrow recovery. Mean
epirubicin, docetaxel and oxaliplatin dose-intensities
were 16.19, 18.48 and 31.90 mg/m2/week, respectively,
which are equivalent at 97.2%, 92.4% and 95.7% of the
planned dose-intensities for these drugs. Grade 3 throm-
bocytopenia was observed in 2.5% of the patients, and
grade 3 anemia occurred in 10% of the patients.
Non-hematological toxicities are listed in Table 4. Mild to
moderate transient peripheral neuropathy occurred in
40% of the patients, while grade 3 developed in two (5%)
patients. In four of these patients (10%) a 25% dose-
reduction of oxaliplatin was required. Alopecia was fre-
quent. Mild nausea and vomiting was encountered in
35% of the patients, and was severe in two (5%) patients.
Grade 1/2 diarrhea occurred in 20% of the patients,
whereas grade 3 was seen in 1 (2.5%) patient. In this
patient a 25% dose-reduction of epirubicin and docetaxel
was required. Hypersensitivity reactions, which not pre-
cluded chemotherapy continuation, were recorded in 5%
of the patients. No cardiotoxicity or treatment-related
deaths were observed.
Discussion
This phase II study of triplet cytotoxic therapy for meta-
static gastric or GEJ adenocarcinoma showed that the
combination of epirubicin, oxaliplatin and docetaxel is an
active and well tolerated regimen as first-line treatment.
Worth of note are the 47.5% RR, the median TTP of 6.3
months, and above all the median OS of 12.1 months
with 50.3% and 12.6% of patients surviving at one year
and two years, respectively. In fact, these results were
obtained in a very poor prognosis patient population,
since liver and/or peritoneal metastases were present in
80% of the cases.
Time to progression for all patients Figure 1
Time to progression for all patients.
Overall survival for all patients Figure 2
Overall survival for all patients.
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Table 2: Objective response in 40 patients
Response No. of patients %
Complete response * 2 5
Partial response * 17 42.5
Stable disease * 13 32.5
Progressive disease 8 20
* Disease control: 80%
Table 3: Grade 3/4 hematological toxicity per cycle and per 
patient
Toxicity % of 220 cycles % of 40 patients
G r a d e  3G r a d e  4G r a d e  3G r a d e  4
N e u t r o p e n i a 2 01 03 51 5
Thrombocytopenia 1 - 2.5 -
Anemia 4 - 10 -Journal of Experimental & Clinical Cancer Research 2009, 28:34 http://www.jeccr.com/content/28/1/34
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The 1-year survival rate, median survival, and overall rate
of response in the present study compare favourably with
several chemotherapy regimens including oxaliplatin
recently used in advanced gastric cancer. In a four-arm
randomized study, 1002 patients with advanced esoph-
agogastric cancer were assigned to receive epirubicin and
cisplatin plus either fluorouracil (ECF) or capecitabine, or
epirubicin and oxaliplatin plus either fluorouracil or
capecitabine (EOX). Although all the treatments were
found equivalent, the EOX regimen produced the best
outcome with a RR of 47.9% and a median OS of 11.2
months [15]. However, it should be noted that about 25%
of the patients had a locally advanced disease as compared
to none in our study. In another phase III study, 220
patients were randomized to receive fluorouracil and leu-
covorin plus either cisplatin or oxaliplatin (FLO). Again,
the FLO regimen fared better with a trend toward
improved median progression-free survival, but no signif-
icant difference in median OS [16]. Apart from peripheral
neuropathy, FLO was also associated with significant less
toxicity.
A better patient compliance along with an improved tol-
erability was observed in the present study when com-
pared with our previous similar study in which epirubicin
and docetaxel were combined with cisplatin [11]. While
RR, TTP and median OS were similar, the inclusion of
oxaliplatin reduced toxicity and prevented the need of G-
CSF administration.
Although the results of this study are of value in support-
ing the use of oxaliplatin in gastric cancer, the main ques-
tion is how the treatment of this disease might be
significantly improved in an era in which chemotherapy-
related benefits seem to have reached a plateau. Further-
more, current practice is increasingly shifting toward to a
more individualized treatment approach. In this regard,
several molecularly targeted agents have proved effective
in combination with chemotherapy in advanced gastric
carcinoma [17].
Given the activity and tolerability, as well as the short time
to response (median, 6 weeks), observed in this study,
EOD may represent an appropriate regimen to be used
also in the neoadjuvant setting and in combination with
targeted agents. However, to better define the role of this
combination comparative trials with other active regi-
mens in gastric cancer (e.g. EOX, FLO) should be carried
out.
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